RU
Rubicon Research Ltd (RUBICON)
₹1,751.50
Mkt cap
₹29,271 Cr
P/E ratio
102.00
P/B
22.43
Div yield
0.08%
ROE
27.00%
ROCE
28.40%
EPS (TTM)
₹17.17
Book value
₹78
52W range
577–1,841
Sector
Healthcare
Price history
Previous close
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]
NSE RUBICONBSE 544578
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−4.86% from high₹1,752
₹577+203.42% from low₹1,841
Current
₹1,751.50
Prev close
₹1,763.00
Day
−0.65%
Price performance
1D
−0.65%
1W
−3.74%
1M
+12.77%
3M
+49.64%
6M
+129.43%
1Y
—
YTD
+164.82%
Financials
Revenue, profit & margin
P/E ratio
102.0×
RUBICON is 200% above the sector median of 34.0×
RUBICON102.0×
Sector median34.0×
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 | |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 | |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 | |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | 24% | |
| Other Income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 | |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 | |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 | |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 | |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | 23% | |
| Net Profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 | |
| EPS in Rs | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | 5.13 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +10.96% · closed higher next day 4 of last 4
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202659.76%Promoter
Promoters59.76%0.10
FIIs7.52%0.02
DIIs9.43%0.59
Public23.29%0.72
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| RUBICON | ₹1,768.30 | 101.56 | 29,271 | 0.08% | 85 | +95.80% | 534 | +51.59% | 28.35% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports1
Concall transcripts11
Credit ratings2
Announcements5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 AugDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 27 Aug - General Atlantic Singapore RR sold 1.4 crore Rubicon shares on 25-26 Aug 2026; holding fell to 27.34%.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 26 Aug - 27th AGM voting results released; 9 resolutions passed, including final dividend, ESOP 2026, and subsidiary merger.Shareholder Meeting / Postal Ballot-Outcome of AGM 26 Aug - Rubicon Research held its 27th AGM on August 26, 2026; discussed dividend, ESOPs, and subsidiary merger proposal.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Aug - Trascript of Earnings Call Q1 FY 2026-27